Insight

Insights,

| Lindsay Bealor Greenleaf, JD, MBA - Head of Policy, Research, and Analysis

Congress just passed the Inflation Reduction Act, with prescription drug policies including government price setting, inflationary penalties, Part D benefit redesign, and a $35 insulin copay cap in Medicare.

Insights,

| Brenna Raines, MHA - Vice President

Medicare Patient Demographics at 340B Covered Entities

Insights,

| Lindsay Bealor Greenleaf, JD, MBA - Head of Policy, Research, and Analysis

Analysis of 2021 Part B Drug Discarded Units in Light of Newly Released Guidance in CY 2023 Medicare Physician Fee Schedule Proposed Rule

Insights,

| Michael Kolodziej, MD, FACP - Senior Advisor

Excitement, Anticipation, Questions Await as ASCO 2022 Begins

Insights,

| Michael Kolodziej, MD, FACP - Senior Advisor

ASCO 2022 is Back the Way it Should Be, in Person

Insights,

ADVI’s Lindsay Bealor Greenleaf spoke to AIS Health about the drug pricing provisions currently being considered in spending bill negotiations and how they would impact the payment & reimbursement of drugs.

Insights,

ADVI Finds New CAR-T DRG 018 Used by 10 New Hospitals in FY 2021 and 11% Increase in Reimbursement

Insights,

ADVI’s Strategic Analytics and Value Economics (SAVES) team found that despite an increase in Part D enrollment in 2020, there was a 12% decrease in the number of Part D beneficiaries reaching catastrophic coverage.

Insights,

After additional guidance and threat of audit from CMS, ADVI re-examined hospital transparency data to find that most hospitals have not updated their pricing information.